Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 172
Filtrer
1.
PLoS One ; 19(5): e0303513, 2024.
Article de Anglais | MEDLINE | ID: mdl-38743748

RÉSUMÉ

OBJECTIVE: Although several acupuncture and moxibustion therapies have been tested in managing breast cancer-related lymphedema (BCRL), there is little consensus regarding the best options for treating this condition. This systematic review and network meta-analysis compared the efficacy of various acupuncture and/or moxibustion therapies for BCRL. METHODS: Seven databases and two clinical registration centers were searched from their inception to December 1st, 2023. The Cochrane Collaboration risk-of-bias assessment tool evaluated the quality of included RCTs. A pairwise meta-analysis was performed in STATA 16.0, while a network meta-analysis was performed in R 4.2.2. RESULTS: 18 studies were included in this analysis. Our results showed that acupuncture and moxibustion methods had great advantages in improving BCRL of patients with breast cancer. In particular, needle-warming moxibustion (NWM) could be the optimal acupuncture and moxibustion method for improving clinical effectiveness and reducing the degree of swelling of affected limbs. CONCLUSION: Our findings suggest that NWM has great potential in treating BCRL. It may reduce arm circumference, lower swelling levels, and improve clinical effectiveness. Nevertheless, more multi-center, high-quality, and large sample RCTs will be needed in the future.


Sujet(s)
Thérapie par acupuncture , Lymphoedème après cancer du sein , Moxibustion , Humains , Moxibustion/méthodes , Moxibustion/effets indésirables , Femelle , Thérapie par acupuncture/méthodes , Thérapie par acupuncture/effets indésirables , Lymphoedème après cancer du sein/thérapie , Méta-analyse en réseau , Résultat thérapeutique , Tumeurs du sein/complications , Tumeurs du sein/thérapie
2.
Clin Breast Cancer ; 24(5): 439-446, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38565462

RÉSUMÉ

BACKGROUND: To investigate whether fluidotherapy added to complete decongestive therapy (CDT) would provide additional contribution to edema reduction in patients with breast cancer related lymphedema (BCRL). MATERIAL AND METHODS: Thirthy-two patients with unilateral BCRL were randomly divided into 2 groups: standard treatment with CDT only (Group 1) and CDT + fluidotherapy (Group 2). All patients underwent phase 1 CDT, which included manual lymphatic drainage, multilayer bandaging, supervised exercises and skin care for a total of 15 sessions, 5 times a week for 3 weeks. Only Group 2 received a total of 15 sessions application of fluidotherapy. Before and after CDT, patients were evaluated for extremity volumes and excess volumes, according to circumferencial measurements of the extremity. Arm pain was evaluated with Visual Analaogue Scale (VAS-Pain). RESULTS: Seventeen patients in Group 1 and 15 patients in Group 2 completed the study. Patients' demographic data and volume measurements were similar at the beginning of the treatment. Limb volumes of both groups were significantly reduced after treatment (P < .001 for both group). Pain significantly decreased (P = .001 for both group). No adverse reactions were recorded. The mean change in volume measurements and VAS-Pain scores of patients in CDT+fluidotherapy group before and after treatment were significantly higher than those in only CDT group (P = .028, P = .020 respectively). CONCLUSION: Fluidotherapy added to CDT reduced pain and edema severity more than standard CDT in the patients with BCRL. As a noninvasive, novel, and effective method, fluidotherapy may be a promising treatment modality for the treatment of lymphedema.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Humains , Femelle , Adulte d'âge moyen , Lymphoedème après cancer du sein/thérapie , Tumeurs du sein/complications , Tumeurs du sein/thérapie , Traitement par apport liquidien/méthodes , Sujet âgé , Drainage lymphatique manuel/méthodes , Adulte , Résultat thérapeutique , Lymphoedème/thérapie , Lymphoedème/étiologie
4.
Lymphat Res Biol ; 22(3): 203-209, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38648290

RÉSUMÉ

Background: Breast cancer survivors (BCSs) have many lifelong symptoms of anxiety, depression, lymphedema, and fatigue that can be exacerbated by sleep disturbance. However, little is known about unique factors contributing to sleep disturbance among BCSs with lymphedema; this requires further investigation to offer appropriate support and treatment to these individuals. Therefore, the objective of this study was to capture perceptions and experiences of lymphedema and sleep among BCSs with lymphedema. Methods and Results: Qualitative description guided data collection and analysis as part of a mixed-methods investigation to characterize sleep disturbance among BCSs with and without lymphedema. The participants were interviewed one-on-one using a semistructured interview guide. Inductive content analysis was completed using an iterative coding approach, condensing, and categorizing to develop four themes. Seven BCSs with lymphedema participated. From their narratives, four themes were developed: (1) mind and body fatigue are exacerbated by sleep disturbance; (2) fatigue impacted fragile coping and support systems; (3) fatigue influenced self-identity and roles in society; and (4) self-management strategies were used for sleep health. Conclusion: The participants' perceptions of sleep disturbances' impact on their lives endorse further investigation into optimal interventions to improve sleep quality and modify these impactful findings to create a higher quality of life for survivorship.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Survivants du cancer , Fatigue , Recherche qualitative , Qualité de vie , Troubles de la veille et du sommeil , Humains , Femelle , Adulte d'âge moyen , Survivants du cancer/psychologie , Fatigue/étiologie , Fatigue/physiopathologie , Fatigue/psychologie , Fatigue/diagnostic , Troubles de la veille et du sommeil/étiologie , Troubles de la veille et du sommeil/psychologie , Troubles de la veille et du sommeil/physiopathologie , Sujet âgé , Lymphoedème après cancer du sein/psychologie , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/diagnostic , Lymphoedème après cancer du sein/thérapie , Tumeurs du sein/complications , Tumeurs du sein/psychologie , Adaptation psychologique , Sommeil/physiologie , Adulte , Lymphoedème/étiologie , Lymphoedème/psychologie , Lymphoedème/anatomopathologie
6.
Breast Cancer Res Treat ; 205(3): 439-449, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38517603

RÉSUMÉ

PURPOSE: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome measures (OMs) are recommended to be used to measure standardized outcome domains to fully assess the burden of the disease and efficacy of interventions? An integral component of a standardized core outcome set (COS) are the OMs used to measure the COS. METHODS: A supplemental online survey was linked to a Delphi study investigating a COS for BCRL. OMs were limited to a maximum of 10 options for each outcome domain (OD). There were 14 ODs corresponding to the International Classification of Functioning, Disability, and Health (ICF) framework and respondents rated the OMs with a Likert level of recommendation. The feasibility of the listed OMs was also investigated for most outpatient, inpatient, and research settings. RESULTS: This study identified 27 standardized OMs with a few ODs having 2-3 highly recommended OMs for proper measurement. A few of the recommended OMs have limitations with reliability due to being semi-quantitative measures requiring the interpretation of the rater. CONCLUSION: Narrowing the choices of OMs to 27 highly recommended by BCRL experts may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields which manage or research BCRL. There is a need for valid, reliable, and feasible OMs that measure tissue consistency. Measures of upper extremity activity and motor control need further research in the BCS with BCRL population.


Sujet(s)
Lymphoedème après cancer du sein , Survivants du cancer , Méthode Delphi , , Humains , Femelle , Lymphoedème après cancer du sein/thérapie , Lymphoedème après cancer du sein/diagnostic , Lymphoedème après cancer du sein/étiologie , /méthodes , Tumeurs du sein/complications , Enquêtes et questionnaires , Qualité de vie , Adulte d'âge moyen , Reproductibilité des résultats
7.
BMJ Open ; 14(3): e076127, 2024 Mar 14.
Article de Anglais | MEDLINE | ID: mdl-38485488

RÉSUMÉ

INTRODUCTION: Breast cancer-related lymphedema (BCRL) is a common postoperative complication of breast cancer. It develops in a chronic and vicious cycle. Once lymphedema occurs, it cannot be cured and bring serious physiological, psychological, social and economic burden to patients. Upper limb functional exercises are an effective and convenient intervention for managing lymphedema. However, the optimal exercise sequence remains unclear. Therefore, we aim to compare the effects of exercise sequences under the guidance of commonly used exercise sequences and lymphatic flow theory. METHODS: An exploratory randomised controlled cross-over trial will be conducted. 32 patients with BCRL are randomly allocated into two groups (group A and group B). Group A patients will perform functional exercise from wrist joint to shoulder joint, and the exercise direction of group B is opposite to that of group A, that is, from shoulder joint to wrist joint end. Exercise time is once a day, each 20-30 min, for 2 weeks. After 2 weeks of washout period, A and B groups of exchange exercise sequences (exercise frequency and duration unchanged). The primary outcome is upper limb circumference, and secondary outcomes are upper limb function and lymphedema symptoms. ETHICS AND DISSEMINATION: This study protocol is presented in accordance with the Standard Protocol Items: Recommendations for Interventional Trials guidelines. All participants will sign a written informed consent. The research ethics regional committee of Shanghai Seventh People's Hospital has approved the study. Regardless of the outcome of this study, the results will be published in open-access journals to ensure public access. TRIAL REGISTRATION NUMBER: ChiCTR2200066463.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Tumeurs du sein/complications , Tumeurs du sein/chirurgie , Études croisées , Chine , Lymphoedème/étiologie , Lymphoedème/thérapie , Lymphoedème après cancer du sein/thérapie , Essais contrôlés randomisés comme sujet
8.
Breast Cancer Res Treat ; 205(2): 359-370, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38424364

RÉSUMÉ

PURPOSE: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome domains (OD) should be measured to assess the burden of the disease and efficacy of interventions? A Core Outcome Set (COS) that promotes standardized measurement of outcomes within the constraints of time influenced by work environments is essential for patients and the multidisciplinary professionals that manage and research BCRL. METHODS: Using Delphi methodology, a multidisciplinary group of BCRL experts (physical and occupational therapists, physicians, researchers, physical therapist assistants, nurses, and massage therapist) completed two waves of online surveys. BCRL expert respondents that completed the first survey (n = 78) had an average of 26.5 years in practice, whereas, respondents who completed the second survey (n = 33) had an average of 24.9 years. ODs were included in the COS when consensus thresholds, ranging from 70% to 80%, were met. RESULTS: A total of 12 ODs made up the COS. Reaching a minimum consensus of 70%; volume, tissue consistency, pain, patient-reported upper quadrant function, patient-reported health-related quality of life, and upper extremity activity and motor control were recommended at different phases of the BCRL continuum in a time-constrained environment. Joint function, flexibility, strength, sensation, mobility and balance, and fatigue met an 80% consensus to be added when time and resources were not constrained. CONCLUSION: The COS developed in this study thoroughly captures the burden of BCRL. Using this COS may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields, which manage or research BCRL.


Sujet(s)
Lymphoedème après cancer du sein , Survivants du cancer , Méthode Delphi , Qualité de vie , Humains , Femelle , Lymphoedème après cancer du sein/thérapie , Lymphoedème après cancer du sein/étiologie , Tumeurs du sein/complications , Enquêtes et questionnaires , Mesures des résultats rapportés par les patients , /méthodes , Adulte d'âge moyen
9.
Integr Cancer Ther ; 23: 15347354241226625, 2024.
Article de Anglais | MEDLINE | ID: mdl-38281117

RÉSUMÉ

PURPOSE: This study aimed to identify determinants that promote the initiation and maintenance of complete decongestive therapy (CDT) as well as effective strategies for mitigating barriers to self-management of lymphedema among breast cancer survivors. METHODS: A descriptive and qualitative design was used. In-depth interviews were conducted with 13 breast cancer survivors who were managing breast cancer-related lymphedema. Interviews were transcribed verbatim. An iterative descriptive data analysis method was employed to examine the data, compare codes, challenge interpretations, and inductively identify themes. RESULTS: A realization that lymphedema requires daily self-management was the primary determinant leading breast cancer survivors to initiate CDT self-management. The determinants for maintaining daily CDT self-management included the perceived effectiveness of CDT, being willing to assume accountability, and perceived efficacy to undertake CDT. Developing strategies to integrate CDT regimens into daily life is key to maintaining CDT self-management of lymphedema. Three core concepts mediate initiation and maintenance of CDT self-management: understanding lymphedema as a chronic condition that can be managed with CDT self-management, being worried about lymphedema exacerbation, and having support from patient peers and family. CONCLUSIONS: Interventions should be tailored to promote the initiation and maintenance of CDT self-management. While clinicians provided knowledge-based and clinical skills-based information, patient peers provided daily life examples, and real-life implementation strategies for CDT self-management. Ongoing patient-provider and patient-peer communication functioned as effective support for maintaining CDT self-management. Reliable and realistic methods of symptom self-assessment are important for maintaining CDT at home.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Survivants du cancer , Lymphoedème , Gestion de soi , Humains , Femelle , Tumeurs du sein/complications , Tumeurs du sein/thérapie , Lymphoedème/étiologie , Lymphoedème/thérapie , Lymphoedème après cancer du sein/thérapie , Résultat thérapeutique
10.
In Vivo ; 38(1): 272-280, 2024.
Article de Anglais | MEDLINE | ID: mdl-38148086

RÉSUMÉ

BACKGROUND/AIM: Disasters can jeopardize breast cancer care and Japan's triple disaster in 2011 (earthquake, tsunami, and nuclear accident) is no exception. However, detailed information is lacking regarding the care of breast cancer related lymphedema (BCRL) following the disaster. We aimed to explore the process by which local patients become aware of BCRL, the problems faced, and the support they require. We also aimed to clarify the effects of the 2011 disaster on experiences related to lymphedema in the target population. PATIENTS AND METHODS: Patients who developed BCRL after breast cancer treatment were recruited from Iwaki city, a municipality located in the southern coastal region of Fukushima (N=16). In-depth, semi-structured, face-to-face interviews were conducted, and the obtained data were appraised using thematic analysis. RESULTS: Five themes related to BCRL were identified: 1) the process of becoming aware of BCRL, 2) troubles or worries/concerns due to BCRL, 3) information sources regarding BCRL management, 4) strategies to cope with BCRL, and 5) the adverse impacts of the 2011 disaster on BCRL management. CONCLUSION: Except for the disaster context, the themes are in line with those of previous studies conducted in the non-disaster context. Nonetheless, there were limited but non-negligible adverse effects of the 2011 disaster on long-term local BCRL management. The findings of this study demonstrate the necessity for individualizing coping strategies against BCRL among healthcare professionals in the Fukushima coastal area and beyond.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Catastrophes , Accident nucléaire de Fukushima , Lymphoedème , Humains , Femelle , Lymphoedème après cancer du sein/épidémiologie , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/thérapie , Tumeurs du sein/complications , Tumeurs du sein/épidémiologie , Tumeurs du sein/thérapie , Japon/épidémiologie
11.
Curr Pharm Des ; 30(1): 63-70, 2024.
Article de Anglais | MEDLINE | ID: mdl-38141193

RÉSUMÉ

BACKGROUND: Post-mastectomy lymphedema is a chronic progressive disease characterized by a significant reduction in quality of life and a range of complications. AIM: To this date, no single treatment method provides pathological correction of the mechanisms associated with tissue reorganization observed in later-stage breast cancer-related lymphedema (BCRL). METHODS: To define a personalized approach to the management of patients with iatrogenic lymphedema, we performed a systematic review of literature without a comprehensive meta-analysis to outline existing molecular- genetic patterns, overview current treatment methods and their efficacy, and highlight the specific tissue-associated changes in BCRL conditions and other bio-engineering approaches to develop personalized therapy. RESULTS: Our results show that several tissue-specific and pathological molecular markers may be found, yet current research does not aim to define them. CONCLUSION: As such, currently, a strong foundation for further research into molecular-genetic changes in lymphedema tissue exists, and further research should focus on finding specific targets for personalized treatment through bio-engineering approaches.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Femelle , Humains , Bioingénierie , Lymphoedème après cancer du sein/thérapie , Lymphoedème après cancer du sein/étiologie , Tumeurs du sein/complications , Mastectomie/effets indésirables , Qualité de vie , Résultat thérapeutique
12.
Support Care Cancer ; 32(1): 5, 2023 Dec 05.
Article de Anglais | MEDLINE | ID: mdl-38051428

RÉSUMÉ

BACKGROUND: The standard therapy for lymphedema of any origin is complex physical decongestive therapy (CDT). It comprises manual lymph drainage (MLD), compression therapy (CT), exercise therapy (ET), skincare, and patient education. Additionally, intermittent pneumatic compression (IPC) can be applied. However, the contribution of MLD to decongestion is repeatedly questioned. PATIENTS AND METHODS: This study re-analyzes a previous study during a 3-week decongestion period, comparing two different types of compression bandaging at the weekend. Sixty-one patients with unilateral breast cancer-related lymphedema were included. The patients received the same therapy (CDT + IPC) except for the different weekend compression bandaging. MLD was performed twice a day on weekdays. The volume of the affected arm was measured on days 1, 5, 8, 12, 15, 19, and 22. For the analysis, the data of both study groups were pooled. RESULTS: During the week, the patients showed a significant volume reduction (- 155.23 mL (week 1), - 101.02 mL (week 2), - 61.69 mL (week 3), respectively; p < 0.001 each) with a high effect size. On the weekends without MLD, they showed a slight, but also significant increase (12.08 mL (weekend 1), 8.36 mL (weekend 2), 4.33 mL (weekend 3), respectively; p < 0.001 each) with a medium effect size. CONCLUSIONS: We showed a strong effect of MLD on volume reduction. Differences from other studies are the larger study population and the more intensive application of MLD. If applied intensively, MLD is strongly decongestive during a 3-week decongestion therapy for breast cancer-related lymphedema.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Drainage lymphatique manuel , Tumeurs du sein/complications , Tumeurs du sein/thérapie , Études rétrospectives , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/thérapie , Lymphoedème/étiologie , Lymphoedème/thérapie , Résultat thérapeutique
13.
Fisioterapia (Madr., Ed. impr.) ; 45(6): 331-340, nov. - dec. 2023. tab
Article de Espagnol | IBECS | ID: ibc-226831

RÉSUMÉ

Objetivo Comparar la evidencia de los diferentes tratamientos para el linfedema y los posibles dolores miofasciales postmastectomía, para conseguir la máxima calidad de vida de los pacientes. Estrategia de búsqueda y selección de estudios Se realizó una búsqueda en las bases de datos PubMed, Phisiotherapy Evidence Database (PEDro) y Web of Science (WOS) durante marzo y abril del año 2022. Se tuvo en cuenta que los pacientes hubiesen sido intervenidos quirúrgicamente por cáncer de mama (CaMama), mayores de 18 años y que los estudios fuesen ensayos clínicos; resultando un total de 10 artículos seleccionados. Se evaluó la calidad metodológica y factor de impacto de cada uno de ellos. Síntesis de resultados Las variables analizadas fueron reducción del linfedema, calidad de vida y abordaje del dolor. El tratamiento a través de drenaje linfático manual (DLM) presentó mejorías en todos los artículos que hacían referencia a la reducción del linfedema, tanto de forma individual como de forma aislada; en cambio, respecto a los dolores miofasciales el tratamiento de liberación miofascial mostró mejoras tanto en la calidad emocional como en la disminución del dolor, siendo más efectivo en esta última variable. Conclusiones Los tratamientos que mejoran la calidad de vida y dolor de los pacientes que han sufrido una intervención quirúrgica debido al CaMama, además de reducir el linfedema son DLM, facilitación neuromuscular propioceptiva (FNP), liberación miofascial y programas de ejercicios y entrenamientos. La limitación principal respecto a los tratamientos, es que no existe ningún programa de intervención específico (AU)


Objective To compare the evidence of the different treatments for lymphedema and possible postmastectomy myofascial pain, to achieve the highest quality of life for patients. Search strategy and selection of studies A search was carried out in the PubMed, Physiotherapy Evidence Database (PEDro) and Web of Science (WOS) databases during March and April 2022. It was taken into account that the patients had undergone surgery surgically for breast cancer, that they were over 18 years of age and that the studies were clinical trials; resulting in a total of 10 selected articles. The methodological quality and impact factor of each of them were evaluated. Summary of results The variables analyzed were reduction of lymphedema, quality of life and pain management. Treatment through manual lymphatic drainage (MLD) presented improvements in all the articles that made reference to the reduction of lymphedema, both individually and in isolation; On the other hand, regarding myofascial pain, myofascial release treatment showed improvements in both emotional quality and pain reduction, being more effective in this last variable. Conclusions The treatments that improve the quality of life and pain of patients who have undergone surgery due to breast cancer, in addition to reducing lymphedema, are manual lymphatic drainage, proprioceptive neuromuscular facilitation, myofascial release, and exercise and training programs. The main limitation regarding treatments is that there is no specific intervention program (AU)


Sujet(s)
Humains , Femelle , Drainage lymphatique manuel , Lymphoedème après cancer du sein/thérapie , Qualité de vie , Tumeurs du sein/chirurgie , Mastectomie
14.
Lymphology ; 56(1): 27-39, 2023.
Article de Anglais | MEDLINE | ID: mdl-38019877

RÉSUMÉ

Acupuncture is a potential therapy for breast cancer-related lymphedema (BCRL). Despite a recent meta-analysis on efficacy, data on acupuncture safety in BCRL are lacking. Current clinical guidelines recommend avoiding needling in the upper extremity affected by lymph node dissection. We undertook a systematic review focusing on acupuncture safety and treatment protocols in clinical trials for BCRL. Literature searches were conducted in PubMed, Ovid, CINAHL, and Cochrane library. Eight clinical trials on acupuncture for BCRL were analyzed. The Standards of Acupuncture intervention (STRICTA 2010) and Cochrane risk of bias (RoB2 2019) were applied to assess methods for acupuncture interventions within Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. Quantity and severity of adverse events (AE) were reviewed. A total of 189 subjects participated in 8 clinical trials with 2965 acupuncture treatments. No serious adverse events (SAE) were reported regardless of treatment laterality or protocol, with only a single grade 2 skin infection in 2,965 total treatments (0.034%), including 1,165 bilateral and 225 ipsilateral treatments. Our comprehensive review of clinical trials of acupuncture for BCRL demonstrated no significant adverse events in 2,965 treatments, including 1,390 in the affected limb. An approach for routine integration of acupuncture into BCRL maintenance therapy is proposed.


Sujet(s)
Thérapie par acupuncture , Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Tumeurs du sein/complications , Tumeurs du sein/thérapie , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/thérapie , Thérapie par acupuncture/effets indésirables , Thérapie par acupuncture/méthodes , Membre supérieur , Lymphoedème/étiologie , Lymphoedème/thérapie
15.
Lymphat Res Biol ; 21(6): 581-584, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37729078

RÉSUMÉ

Background: A recently completed clinical trial compared a novel nonpneumatic compression device (NPCD) with a traditional advanced pneumatic compression device (APCD) for the treatment of breast cancer-related lymphedema (BCRL); the study revealed that the NPCD produced superior clinical and quality-of-life (QOL) outcomes. In this subanalysis, we sought to examine these results within the subset of trial subjects aged ≥65 years. Methods: A randomized crossover head-to-head trial was conducted to compare the NPCD with a commercially available APCD. Patients were randomly assigned to one or the other device for 28 days of use, followed by a 4-week washout period before a comparable 28-day utilization of the alternate device. Limb edema, adherence to daily device use, and QOL measures were collected at day 0 and 28 of each period. Results: A total of 14 subjects were aged ≥65. During NPCD use, subjects experienced a mean decrease in limb edema of 100.3% (p = 0.0082) as well as improvements in mean overall and subscale scores of the Lymphedema Quality of Life Questionnaire (LYMQOL). By comparison, during APCD use limb edema decreased by a mean of 2.9% (p = 0.8899) with no significant changes in any LYMQOL scores. Mean adherence was significantly higher during NPCD use (96.6%) than during APCD use (58.3%, p < 0.0001). Conclusions: The novel NPCD produced superior clinical and QOL outcomes in older subjects with BCRL. ClinicalTrials.gov ID: NCT04908254.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Sujet âgé , Femelle , Qualité de vie , Tumeurs du sein/complications , Études croisées , Lymphoedème après cancer du sein/diagnostic , Lymphoedème après cancer du sein/thérapie , Lymphoedème/diagnostic , Lymphoedème/étiologie , Lymphoedème/thérapie , Oedème , Résultat thérapeutique
16.
Rehabilitación (Madr., Ed. impr.) ; 57(3): [100777], Jul-Sep. 2023. tab, graf
Article de Anglais | IBECS | ID: ibc-222914

RÉSUMÉ

Introduction and objectives: Currently, the assessment of lymphoedema related to breast cancer (BCRL) is performed through the global perimeter volumetry. We implemented an additional system with partial measures (hand, forearm, and upper arm) that allows us to approximate the segmental distribution of oedema. We used this measurement tool to determine the oedema distribution and its evolution, as well as its possible impact on clinical assessment. Methods: We carried out a retrospective observational study of the patients referred to our service with suspected BCRL. Inclusion criteria: Unilateral breast cancer, availability of global and partial digital medical record, and follow-up for a minimum of 24 months. Of the 210 selected patients, 190 were considered affected (≥10% excess volume). We analysed at three time points (initial, final, and peak involvement) the oedema distribution and segmental predominance and its relationship with the evolutionary course and the severity of the process. We subsequently examined, at the initial timepoint, the concordance of the global assessment with the partial assessment for the clinical classification of the 210 patients in the initial sample. Results: The BCRL oedema was characteristically irregular, with the forearm being the most affected segment and the hand the least affected (RM ANOVA: p<0.001). The irregularity was related to its severity (χ2: p<0.001) and the evolutionary course (Student t-test: p<0.005 for the hand). Overall, disagreement of 46.67% was observed between the clinical classification of the global and partial assessment. Conclusions: This work supports the need to add partial volumetry to the commonly used global assessment.(AU)


Introducción y objetivos: Actualmente la volumetría perimetral global se utiliza para valorar el linfedema relacionado con cáncer de mama (LRCM). Nosotros implementamos un sistema adicional que permite aproximarse a la distribución segmentaria del edema mediante tres indicadores parciales: mano, antebrazo y brazo. Utilizamos esta herramienta para conocer la distribución del edema, su evolución y su posible repercusión en la valoración clínica. Metodología: Se realizó un estudio observacional retrospectivo de los pacientes remitidos a nuestro servicio con sospecha de LRCM. Criterios de inclusión: Cáncer de mama unilateral, con registros volumétricos en la historia clínica digital y 24 meses de seguimiento mínimo. De los 210 pacientes seleccionados, en 190 pacientes afectos (≥10% de exceso de volumen) se analizaron en tres momentos de medición (inicial, final y máxima afectación) la distribución del edema, su predominio segmentario y la relación con la evolución y la gravedad del proceso. Posteriormente se examinó la concordancia de los indicadores globales con los parciales en la valoración clínica de los 210 pacientes de la muestra inicial. Resultados: El LRCM fue característicamente irregular, siendo el antebrazo el segmento predominante y la mano el menos afecto (MR ANOVA: p<0,001). La irregularidad se relacionó con la gravedad del proceso (chi cuadrado: p<0,001) y su evolución (t de Student: p<0,005 para la mano). Además, se apreció, en conjunto, una discordancia en la valoración clínica del índice global con los índices parciales del 46,67% (W de Kendall=0,467). Conclusión: El estudio apoya la necesidad de añadir volumetría parcial a la valoración global habitualmente utilizada.(AU)


Sujet(s)
Humains , Femelle , Lymphoedème après cancer du sein/traitement médicamenteux , Lymphoedème après cancer du sein/thérapie , Lymphoedème après cancer du sein/diagnostic , Dossiers médicaux électroniques , Tumeurs du sein , Réadaptation , Services de Réhabilitation , Titrimétrie , Études rétrospectives
17.
Trials ; 24(1): 549, 2023 Aug 22.
Article de Anglais | MEDLINE | ID: mdl-37608354

RÉSUMÉ

BACKGROUND: Lymphedema is a common complication following breast cancer treatment. The aim of this study is to evaluate the effectiveness of a self-adjusting compression garment (ReadyWrap®) in reducing (phase 1) and maintaining (phase 2) upper limb volume in women presenting breast cancer-related lymphedema. METHODS: This study will comprise a randomized, controlled, single-blind clinical trial concerning women with breast cancer-related lymphedema undergoing treatment at a public cancer treatment reference hospital in the city of Rio de Janeiro, Brazil. The intervention will be carried out by adapting self-dressing versus the standard treatment of compressive bandaging (phase 1) and compressive mesh (phase 2). Both groups will be assessed at the beginning and end of intensive treatment and followed up for up to 12 months to evaluate immediate and late outcomes. Assessments will be carried out by physical upper limb examination (inspection, palpation, volume, dynamometry, and thermography) and questionnaires application to assess patient's quality of life pertaining to the health, functionality, and symptoms of the affected upper limb, as well adverse effects and adherence to treatment. Data will be analyzed descriptively and analytically through univariate and multiple linear regressions. P values < 0.05 will be considered statistically significant. DISCUSSION: This study will evaluate the effectiveness of a self-adjustable garment (ReadyWrap®) in the treatment of lymphedema secondary to breast cancer in Brazilian women compared to the gold standard treatment for limb volume reduction (phase 1) and maintenance (phase 2) phases comprising, respectively, a compressive bandaging and a compressive mesh. The outcome results will provide data based on both quantitative responses and self-reported participant outcomes. The study will also assess the cost-effectiveness of the ReadyWrap® treatment versus standard care. Finally, we expect to reaffirm one more product/therapy as a treatment for this extremely complex and impactful condition following the data analysis. TRIAL REGISTRATION: NCT04934098 [Clinical trials phase 1]. Registered on June 22, 2021. NCT04881604 [Clinical trials phase 2]. Registered on May 11, 2021.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Brésil , Tumeurs du sein/complications , Qualité de vie , Méthode en simple aveugle , Techniques de physiothérapie , Lymphoedème après cancer du sein/diagnostic , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/thérapie , Lymphoedème/diagnostic , Lymphoedème/étiologie , Lymphoedème/thérapie , Essais contrôlés randomisés comme sujet
18.
Lymphat Res Biol ; 21(6): 549-555, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37582209

RÉSUMÉ

Breast cancer-related lymphedema is a condition occurring after a partial or full mastectomy, where there is a buildup of interstitial fluid in the body, particularly in the upper limb. There is a lack of at-home sensors that can help monitor the progression of lymphedema. The purpose of this scoping review is to gather relevant information on sensors for remote lymphedema monitoring. A literature search of Medline, PubMed, Scopus, Web of Science, and BMC databases yielded 96 studies. A total of six studies were selected for data extraction. Data were extracted from each study and organized into tables for analysis. A total of six different devices were mentioned in the six studies included in the scoping review, divided into wearable and nonwearable sensors. Nonwearable sensors were more likely to be adaptable for remote sensing as they were further along in development and commercially available on the market. Nonwearable sensors are more developed than wearable sensors for the purpose of remote lymphedema monitoring. This review advocates further development and validation of sensors for lymphedema management, particularly for remote monitoring and health assessments.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Mastectomie , Lymphoedème/diagnostic , Lymphoedème/étiologie , Membre supérieur , Lymphoedème après cancer du sein/diagnostic , Lymphoedème après cancer du sein/étiologie , Lymphoedème après cancer du sein/thérapie
19.
BMJ Open ; 13(7): e071630, 2023 07 10.
Article de Anglais | MEDLINE | ID: mdl-37429694

RÉSUMÉ

INTRODUCTION: Breast cancer-related lymphoedema (BCRL) is one of the most underestimated and debilitating complications associated with the treatment that women with breast cancer receive. Several systematic reviews (SRs) of different physical exercise programmes have been published, presenting disperse and contradictory clinical results. Therefore, there is a need for access to the best available and summarised evidence to capture and evaluate all the physical exercise programmes that focus on reducing BCRL. OBJECTIVE: To evaluate the effectiveness of different physical exercise programmes in reducing the volume of lymphoedema, pain intensity and improving quality of life. METHOD AND ANALYSIS: The protocol of this overview is reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, and its methodology is based on Cochrane Handbook for Systematic Reviews of Interventions. Only those SRs involving physical exercise by patients with BCRL will be included, whether on its own or combined with other exercises or other physical therapy interventions.The outcomes of interest to be considered will be lymphoedema volume, quality of life, pain intensity, grip strength, range of motion, upper limb function and any adverse event. The MEDLINE/PubMed, Lilacs, Cochrane Library, PEDro and Embase databases will be searched for reports published from database inception to April 2023.Two researchers will perform study selection, data extraction and risk of bias assessment independently. Any discrepancy will be resolved by consensus, or ultimately, by a third-party reviewer. We will use Grading of Recommendations Assessment, Development and Evaluation System to assess the overall quality of the body of evidence. ETHICS AND DISSEMINATION: The results of this overview will be published in peer-reviewed scholarly journals and the scientific dissemination will take place in national or international conferences. This study does not require approval from an ethics committee, as it does not directly collect information from patients. PROSPERO REGISTRATION NUMBER: CRD42022334433.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Femelle , Humains , Lymphoedème après cancer du sein/thérapie , Tumeurs du sein/complications , Maladie chronique , Exercice physique , Traitement par les exercices physiques , Lymphoedème/étiologie , Lymphoedème/prévention et contrôle , Qualité de vie , Revues systématiques comme sujet
20.
Int J Biometeorol ; 67(9): 1505-1507, 2023 Sep.
Article de Anglais | MEDLINE | ID: mdl-37407784

RÉSUMÉ

Lymphedema is a chronic and progressive disorder of the lymphatic system that impairs the return of lymphatic fluid. Breast cancer treatment can cause breast cancer-related lymphedema (BCRL), with axillary lymph node dissection and regional lymph node radiation being established risk factors. BCRL can cause severe morbidity, disability, and reduced quality of life. Early detection and treatment are essential to prevent the disease from progressing and causing complications. According to the International Society of Lymphology, complex decongestive therapy (CDT) is the most effective conservative treatment for lymphedema. Aquatic exercise is a safe and effective form of therapeutic CDT exercise that can improve joint range of motion, reduce pain, and positively impact limb volume. Additionally, health resort medicine and thermal mineral-rich waters may provide synergistic benefits for therapeutic exercise programs. Therefore, we believe that consideration should be given to whether the spa setting could represent a viable alternative for the rehabilitation of BCRL patients.


Sujet(s)
Lymphoedème après cancer du sein , Tumeurs du sein , Lymphoedème , Humains , Femelle , Tumeurs du sein/complications , Tumeurs du sein/anatomopathologie , Tumeurs du sein/thérapie , Qualité de vie , Stations de cure , Lymphoedème après cancer du sein/thérapie , Lymphoedème après cancer du sein/complications , Lymphoedème/étiologie , Lymphoedème/prévention et contrôle
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...